Tuesday, January 9, 2018

Erlotinib - USA


IPR decision:

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Status
IPR2016-01284
06/28/2016
01/09/2017
Apotex, Inc
US 6,900,221
Final Written Decision (Claims 44‒46 and 53 are Unpatentable)

PTAB concluded that Petitioner has demonstrated that the preponderance of the evidence of record supports that it would have been obvious to the ordinary artisan at the time of invention to combine Schnur with either OSI’s 10-K or Gibbs, with a reasonable expectation of success.

No comments:

Post a Comment